Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global probiotic supplements market size is expected to grow from $6.97 Billion in 2021 to $11.52 Billion by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028, according to a report by the Insight Partners.
read more
The global immune health supplements market forecast is expected to grow at a CAGR of 10.2% from 2022 to 2032. The market is expected to reach a valuation of approximately U$ 61B by 2032, according to a report by Future Market Insights.
read more
Products offered by the leading players in the global metallic stearates market are used as active ingredients in a diverse range of end-use industries, including paints, lubricants, construction materials, personal care products, cosmetics, and detergents, among others, according to a report by Transparency Market Research.
read more
NeuroSense Therapeutics, a company developing treatments for severe neurodegenerative diseases, announced results from its multi-dose PK study of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). It is expected that these PK data, combined with the current Phase IIb PARADIGM study, will assist NeuroSense in ...
read more
The global Alzheimer’s disease therapeutic market size is expected to grow by $3.99B, accelerating at a CAGR of 8.76% between 2021 and 2026, according to a report by Technavio.
read more
The global microbiome therapeutics market size is expected to reach $ 973.63 million by 2030, garnering a CAGR of 31.24% from 2022 to 2030, according to a report from Research & Markets. The rise in prevalence of target diseases such as gastrointestinal diseases, diabetes, and immunological indications is anticipated to drive growth.
read more
ACG, an integrated pharmaceutical and nutraceutical manufacturer, announced that Shankar Gupta will be re-joining the business in the newly created role of chief sales officer.
read more
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced the opening of its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus.
read more
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no ...
read more
The global gelatin market size reached US$ 3.1 billion in 2021 and is likely to grow at a CAGR of 5.8% during the forecast period (2022-2032), totaling around $5.9B by the end of 2032, according to a report from Fact.MR.
read more
Takeda Canada announce that Health Canada has authorized LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.
read more
Zelira Therapeutics, a company that commercializes clinically validated cannabinoid medicines, launches ZYRAYDI™, its patented, licensable technology for the medical cannabis industry.
read more
Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the pharmaceutical industry, announced the appointment of Derek Hennecke as an independent member of its board of directors.
read more
Roquette, a provider of pharmaceutical and nutraceutical excipients, announces its complete acquisition of India-based excipient manufacturer, Crest Cellulose.
read more
Aurinia Pharmaceuticals, a biopharmaceutical company specializing in autoimmune diseases, announced that the European Commission (EC) has granted marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).
read more